当前位置：药药网 / 医药文献 /临床试验研究设计终点和生物标志物药物安全性(本栏目收费,不能显示细节,电话13136136841)
关键字：
类型：
下载页码(大于等于0,小于611)：
临床试验研究设计终点和生物标志物药物安全性 890条(本栏目收费,不能显示细节,电话13136136841)
manual techniques coin toss,118
118
sealed envelopes,115–119
115 119
Alzheimer’s disease randomization code breaking example,119–120
119 120
Amendments Clinical Study Protocol,48–50
48 50
Amino acids characteristics and pharmacological importance,9–11
9 11
AML see Acute myeloid leukemia Anatomical Therapeutic Chemical (ATC) system,565
565
Antibody drugs origins,7–9
7 9
Antibody-dependent cell cytotoxicity (ADCC),481,486,498–499
481 486 498 499
APL see Acute promyelocytic leukemia Approval Letter,603
603
Arthritis health-related quality of life,404
404
Asthma immune response,506
506
ductal carcinoma in situ,100–101
100 101
invasive breast cancer,101
101
lobular carcinoma in situ,100–101
100 101
time to distant metastasis and prognostic factors in breast cancer gene array,267–268
267 268
microRNA expression,268
268
Bristol-Myers Co. v. Gonzales,570
570
Bristol-Myers Squibb Co. v. Rhone-Poulenc Rorer Inc,620
620
Capecitabine thymidine phosphorylase as survival biomarker,249
249
Cappuzzo study,245–246
245 246
Carboplatin Maemondo study,221–224
221 224
Case Report Form (CRF)follow up reports,446–447
446 447
Chronic lymphocytic leukemia (CLL)clinical features,287–288
287 288